Check for updates

OPEN ACCESS

EDITED BY Paul Yoo, University of Toronto, Canada

REVIEWED BY

Bowen Chang, The First Affiliated Hospital of University of Science and Technology of China Anhui Provincial Hospital, China Matthew O. Fraser, Duke University, United States

*CORRESPONDENCE Zhongbao Zhou 346894383@qq.com Jitao Wu wjturology@163.com

[†]These authors have contributed equally to this work and share first authorship

SPECIALTY SECTION

This article was submitted to Neurorehabilitation, a section of the journal Frontiers in Neurology

RECEIVED 01 May 2022 ACCEPTED 26 July 2022 PUBLISHED 13 September 2022

CITATION

Yao H, Zhang X, Sun F, Tang G, Wu J and Zhou Z (2022) The efficacy of intravaginal electrical stimulation (IVES) in treating female with urinary incontinence symptom from meta-analysis of nine randomized controlled trials. *Front. Neurol.* 13:933679. doi: 10.3389/fneur.2022.933679

COPYRIGHT

© 2022 Yao, Zhang, Sun, Tang, Wu and Zhou. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

The efficacy of intravaginal electrical stimulation (IVES) in treating female with urinary incontinence symptom from meta-analysis of nine randomized controlled trials

Huibao Yao^{1†}, Xiaofei Zhang^{2†}, Fengze Sun^{1†}, Gonglin Tang¹, Jitao Wu^{1*} and Zhongbao Zhou^{1,3*}

¹Department of Urology, The Affiliated Yantai Yuhuangding Hospital of Qingdao University, Yantai, China, ²Department of Neurology, The Affiliated Yantai Yuhuangding Hospital of Qingdao University, Yantai, China, ³Department of Urology, Beijing TianTan Hospital, Capital Medical University, Beijing, China

Background: Urinary incontinence (UI) is a common disease in the middle-aged and elderly women, and physical therapy has gradually become the mainstream treatment of UI. We conducted a meta-analysis to evaluate the efficacy of intravaginal electrical stimulation (IVES) in the treatment of UI.

Methods: From January 2006 to December 2021, we finally selected nine randomized controlled trials (RCTs) including 657 participants from PubMed, EMBASE, and Cochrane databases to evaluate the efficacy of IVES in the treatment of female UI. Continuous data were represented by mean difference and 95% CI, while dichotomous data were represented by odds ratio and 95% CI. All the data were analyzed by the Review Manager Version 5.4.

Results: Compared with the control group, there were significant improvements in urine pad test (P = 0.01), urinary incontinence frequency (P = 0.04), some indicators in the incontinence quality of life questionnaire and King's health questionnaires, and subjective feeling of cure (P = 0.009) in the IVES group. However, in other indicators reflecting UI, there was no significant difference between the IVES group and the control group. In addition, subgroup analysis showed that IVES and IVES combined with training could significantly reduce the weight of the urine pad, which reflected the improvement of urine leakage.

Conclusion: This meta-analysis proved that IVES can partially improve the symptoms of female patients with UI compared with the control group. However, it still needs to be further evaluated through more high-quality research in the future.

KEYWORDS

intravaginal electrical stimulation, women, urinary incontinence, randomized controlled trials, meta-analysis

Introduction

Urinary incontinence (UI) is a common disease, which is defined as the phenomenon of transurethral urine leakage that is not controlled by will by the International Conference Society (ICS) (1). Women are more likely to suffer from UI than men due to age growth, improper postpartum care, congenital urogenital abnormalities, and previous gynecological surgery (2–5). Although UI will not endanger the life of patients, long-term suffering from UI will seriously affect the physical and mental health, and the quality of life of patients. Patients will deliberately avoid going out, reduce social activities, and gradually become disconnected from society. Therefore, urinary incontinence is also known as "social cancer" (6–8).

Physical therapy is usually used as the first-line therapy of UI treatment, including pelvic floor muscle training, bladder training, intravaginal electrical stimulation (IVES), and other methods (9, 10). Intravaginal electrical stimulation (IVES) can inhibit the activity of the reflex parasympathetic nerve and reduce the involuntary contraction of the bladder detrusor (11, 12). Other studies have also shown that IVES stimulate pelvic floor muscle contraction and relaxation directly through the sensors in the vagina, increasing pelvic floor muscle strength, and effectively improving UI symptoms (13). However, due to embarrassment, discomfort, and other shortcomings, its clinical use rate is not high now (14).

We conducted a meta-analysis of the retrieved randomized controlled trials (RCTs) to evaluate the efficacy of IVES in the treatment of female urinary incontinence.

Materials and methods

Search strategy

We searched related literature from PubMed, Embase, and Cochrane databases according to the guidelines of Preferred Reporting Items for Systematic Reviews and Meta-Analysis (PRISMA) (15), and the retrieval time was limited from January 2006 to December 2021. We formulated the retrieval strategy according to the PICOS (populations, interventions, comparators, outcomes, and study designs) principle. The keywords searched are as follows: electrical stimulation, intravaginal electrical stimulation, female, women, incontinence, urinary incontinence, RCT, and randomized controlled trials. There were no restrictions on the language of the article when searching the literature. The two authors searched according to the search strategy, then compared the search results, respectively. All the articles retrieved were read independently by two researchers. In case of dispute, a third researcher would be invited to read and provide suggestions to reach an agreement. In addition, we would

also download and read some references to related articles if necessary.

Inclusion and exclusion criteria

All the articles included are supposed to meet the criteria as follows: (1) the articles describing IVES in treating women's urinary incontinence; (2) every article's content should be obtained and all the data are true and effective; (3) the experimental method is a randomized controlled trial. If the same research is published repeatedly in different journals or at different times, we would select the latest research literature for this meta-analysis. In addition, if an article type is a case report, review article, meeting report, or abstract, this article would be excluded. The relevant details of inclusion criteria and exclusion criteria are shown in Table 1.

Quality assessment

We evaluated all included randomized controlled trials studies according to the guideline of the *Cochrane Handbook for Systematic Reviews of Interventions v5.10.* At the same time, each article was classified according to the following three quality evaluation criteria: (+) low risk of bias, (?) moderate risk of bias or insufficient evidence to judge the degree of bias, and (-) high risk of bias. All the authors participated independently in the risk assessment of each RCT. After the evaluation was completed, everyone summarized and discussed until all the evaluation results were consistent.

Data extraction

Two authors independently collected data from the included articles and tabulated them. The extracted data include (a) first author's name, (b) published year, (c) country, (d) sample size of experimental group and control group, (e) setup of experimental group and control group, (f) methodology, and (g) outcome indicators. This study did not need ethical approval since it was a retrospective analysis of published research.

Statistical analyses

The data in this study were analyzed by Review Manager Version 5.4.0 (Cochrane Collaboration, Oxford, UK). We used fixed or random effect models to evaluate the indicators. The continuous data type was expressed by mean difference (MD)

TABLE 1 Search strategy according to populations, interventions, comparators	, outcomes, and study designs (PICOS).
--	--

	Population	Intervention	Comparator	Outcomes	Study design
Inclusion criteria	Women with urinary	Intravaginal electrical	Placebo Training	Pad test	Randomized
	incontinence	stimulation	Other	Bladder diary	Controlled Trials
			electrical stimulation	King's health	
				questionnaire	
				I-QOL questionnaire	
				PFM strength	
				Subjective feeling	
Exclusion Criteria	Not performed	Not performed	Not performed	Not performed	Letters, comments,
					reviews, meeting
					reports
					reports

and 95% confidence interval (CI), while the dichotomous data type was expressed by odds ratio (OR) and 95% CI. In addition, we tested the heterogeneity by *Q*-value test or I^2 test. If the P < 0.05 in the *Q*-value statistic test or I^2 was greater than 50% in the I^2 test, the study was considered to be heterogeneous and would be analyzed by the random effect model. Otherwise, the study would be analyzed by a fixed effect model because of homogeneity. In the results section, the data with *P*-value < 0.05 were considered statistically significant.

Results

Study selection, search results, and characteristics of the trials

We searched and finally found 70 articles according to the aforementioned search strategy and another 49 articles were deleted when we first screened the titles and abstracts. An additional seven articles, of the remaining 21 articles were excluded because they lacked relevant data. Five duplicate articles were excluded from the remaining 14 articles, and at last, nine randomized controlled trials were included in our study to evaluate the efficacy of IVES in improving UI symptoms (16–24). The process of study selection is presented in Figure 1, and the characteristics of these studies are shown in Table 2.

Risk of bias

All included studies in this meta-analysis were randomized controlled trials. The summary and graph of bias risk are shown in Figures 2, 3.

Pad test

The urine pad test of seven randomized controlled trials involving 491 patients (266 in the vaginal electrical stimulation group and 225 in the control group) showed that the weight (unit: g) of the urine pad in the vaginal electrical stimulation group decreased significantly (MD = -6.34; 95% CI = [-11.24, -1.45]; P = 0.01) compared with the control group and the difference was statistically significant (Figure 4). The data involved in the analysis adopts the change value or final value before and after processing.

Bladder diary

Incontinence episodes

Overall, six of the nine articles provided data on changes in the average number of episodes of urinary incontinence *per* 24 h, and the meta-analysis used a random effect model. The results showed that compared with the control group, the average number of episodes of urinary incontinence in the vaginal electrical stimulation group was significantly reduced (MD = -1.01, 95% CI = [-1.99, -0.03], P = 0.04; Figure 5A).

Nocturia episodes

Nocturia episodes refer to the number of times a person gets up and urinates at night after falling asleep. Four RCTs comprising 245 patients (148 and 97 in the experimental and control groups, respectively) described the change in the number of nocturia episodes per night. The results reported that there was no significant difference in the efficacy of IVES on nocturia episodes compared with the control group (MD = -0.68, 95% CI = [-1.49, 0.12], P = 0.10; Figure 5B).



Daytime micturition episodes

Daytime micturition episodes refer to the number times a person urinates during the daytime, and the normal range is usually from four to six times. Among the nine included studies, six articles provided the mean number of daytime micturition data. The results identified that there was no significant difference in reducing the number of nocturnal urination in the treatment group compared with the control group (MD = -0.84, 95% CI = [-1.92, 0.24], P = 0.13; Figure 5C).

Frontiers in Neurology

TABLE 2 Characteristics of all the studies.

Author's name	Year	Country	Sample	size	Set	tup	Methodology	Outcome	
			Experimental group	Control group	Experimental group	Control group			
Amaro et al. (18)	2006	Brazil	20	20	• electrical stimulator: Dualplex Uro 996	• electrical stimulator: Dualplex Uro 996	 20 mins/time 3 times/week	 pad test urodynamic study	
					 frequency: 4 Hz pulse width: 700 μs site of action: vagina 	same type of vaginal probe without electrical energysite of action: vagina	• 7 weeks		
Correia et al. (16) ^a	2013	Brazil	15	15	 electrical stimulator: Dualpex 961 (Quark Medical Products) frequency: 50 Hz pulse width: 700 μs site of action: vagina 	 electrical stimulator: Dualpex 961 (Quark Medical Products) frequency: 50 Hz pulse width: 700 μs site of action: suprapubic region 	 20 mins/time 2 times/week 6 weeks	 pad test pelvic floor muscle strength King's Health Questionnaire 	
Correia et al. (16) ^b	2013	Brazil	15	15		and ischial tuberosityNo treatment			
Dmochowski et al. (21)	2019	America	91	89	 electrical stimulator: iTouch sure (TensCare Ltd, Epsom, Surrey, UK) frequency: 50 Hz pulse width: 300 μs site of action: vagina 	 electrical stimulator: INNOVO[®] (Atlantic Therapeutics, Galway, Ireland) frequency: 50 Hz pulse width: 620 μs site of action: around the pelvic area 	 30 mins/time 5 times/week 12 weeks	 pad test Incontinence Quality o Life bladder diary 	
Elmelund et al. (24)	2018	Denmark	14	13	 pelvic floor muscle training electrical stimulator: Cefar Peristim Pro[®] (NMKimport, Værløse, DK) frequency: 40 Hz pulse width: 250 μs site of action: vagina 	• pelvic floor muscle training	7 time/weeks12 weeks	 ICIQ-UI-SF urethral pressure reflectometry bladder diary pad test 	
Franco et al. (17)	2011	Brazil	20	22	 electrical stimulator: Dualpex 961 (Quark Medical Products) frequency: 10 Hz pulse width: 700 μs site of action: vagina 	 electrical stimulator: Dualpex 961 (Quark Medical Products) frequency: 20 Hz pulse width: 200 μs site of action: Plantar arch of left foot 	 30 mins/time 1 time/week 12 weeks	 Incontinence Quality of Life SF-36 quality of life scale 	

(Continued)

10.3389/fneur.2022.933679

_
Ŧ
Ó
Ū.
₫.
ē
S.
~
6
ĉ
3
<u>o</u>
0
õ
~

TABLE 2 (Continued)

	Year	Country	Sample	size	Se	tup	Methodology	Outcome
	Experimental Control Exper group group		Experimental group	Control group				
Terlikowski et al. (22)	2013	Poland	64	29	 electrical stimulator: VeriProbe (Verity Medical) frequency: 10–40 Hz pulse width: 200–250 μs 20 mins/time site of action: vagina 	 electrical stimulator: VeriProbe (Verity Medical) frequency: 2 Hz pulse width: 50 μs site of action: vagina 	 Experimental 20 mins/time 2 times/week 8 weeks Control 2 seconds/time 2 times/week 	 Incontinence Quality of Life bladder diary pad test
Ugurlucan et al. (19)	2013	Turkey	35	17	 electrical stimulator: Endomed-M 433 (Delf Instruments Physical Medicine B.V.) frequency: 10–50 Hz pulse width: 300 µs or 1 ms maximal output current: 24–60 mA site of action: vagina 	 electrical stimulator: Urgent PC Neuromodulation System frequency: 20 Hz pulse width: 200 μs site of action: 3–4 cm cephalad to the medial malleolus 	 8 weeks 20 mins/time 3 times/week 6-8 weeks 	 bladder diary pad test pelvic floor muscle strength King's Health Questionnaire subjective evaluation
Wang et al. (20)	2017	China	40	80	 site of action: vagina electrical stimulator: PHENIX USB 4 neuromuscular stimulation therapy system (Electronic Concept Lignon Innovation, Montpellier, France) frequency: 12.5–30 Hz site of action: vagina 	 electrical stimulator: G6805-2 Multi-Purpose Health Device (Shanghai Medical Instruments High-Techno, Shanghai, China) frequency: 2 Hz pulse width: 2 ms site of action: sacrococcygeal joint and tip of the coccyx 	 Experimental 45 mins/time 3 times/week 4 weeks Control 60 mins/time 3 times/week 3 weeks 	subjective evaluationpad numbersubjective evaluation
Yildiz et al. (23)	2021	Turkey	29	29	 bladder training and electrical stimulator: Enraf Nonius Myomed 632 frequency: 10 Hz pulse width: 100 ms site of action: vagina 	 bladder training 	 20 mins/time 3 times/week 8 weeks 	 bladder diary pad test pelvic floor muscle strength IIQ7 OAB-V8 subjective evaluation

	Random sequence generation (selection bias)	Allocation concealment (selection bias)	Blinding of participants and personnel (performance bias)	Blinding of outcome assessment (detection bias)	Incomplete outcome data (attrition bias)	Selective reporting (reporting bias)	Other bias
Funda 2012	•	•	•	•	?	•	•
Grasie'la 2014 a	•	+	•	•	+	•	•
Grasie'la 2014 b	•	•	•	•	•	•	•
Joao 2006	•	•	•	•	•	•	•
Maria 2011	?	?	•	•	•	•	•
Marlene 2018	•	•	•	•	•	•	•
Necmettin 2021	•	•	•	•	•	•	•
Robert 2013	•	•	•	•	?	•	•
Roger 2019	•	•			•	•	•
Siyou 2017		+	•	+	+	+	Ŧ



	Expe	erimenta	al	C	ontrol			Mean Difference	Mean Difference
Study or Subgroup	Mean	SD	Total	Mean	SD	Total	Weight	IV, Random, 95% CI	IV, Random, 95% Cl
Amaro 2006	-5.87	5	20	-1.98	5	20	20.2%	-3.89 [-6.99, -0.79]	-
Correia 2014 a	0.41	0.78	15	3.31	12.1	15	16.4%	-2.90 [-9.04, 3.24]	
Correia 2014 b	0.41	0.78	15	7.62	15.27	15	14.2%	-7.21 [-14.95, 0.53]	
Dmochowski 2019	-9.89	19.99	91	-13.07	21.53	89	16.4%	3.18 [-2.89, 9.25]	
Elmelund 2018	-48.61	96.44	12	-19.55	49.48	11	0.6%	-29.06 [-90.97, 32.85]	
Terlikowski 2013	6.1	11.4	64	18.2	20.8	29	13.8%	-12.10 [-20.17, -4.03]	
Ugurlucan 2012	-14.2	15.3	35	-10.6	37	17	5.4%	-3.60 [-21.90, 14.70]	
Yildiz 2021	7.05	11.97	29	26.65	20.69	29	13.0%	-19.60 [-28.30, -10.90]	
Total (95% CI)			281			225	100.0%	-6.34 [-11.24, -1.45]	•
Heterogeneity: Tau ² =	28.27; C	hi² = 22	.57, df	= 7 (P =	0.002);	l² = 699	6		
Test for overall effect:	Z= 2.54	(P = 0.0	1)						-100 -50 0 50 100 Experimental Control

FIGURE 4

Forest plots showing the improvement of pad test by IVES treatment. SD, standard deviation; IV, inverse variance; CI, confidence interval; df, degrees of freedom.

Number of urine pads

Changes in the number of urine pads used per day were also reported in randomized controlled trials. Four randomized controlled trials involving 373 patients (204 in the experimental group and 169 in the control group) described that compared with the control group, the results of the experimental group were not statistically significant (MD = -0.89,95% CI = [-2.10, 0.31], P = 0.15; Figure 5D).

King's health questionnaire

The King's health questionnaire is usually used as a quality-of-life evaluation index for female patients with urinary incontinence because it is easy to manage and increases the objectivity of patients' descriptions of subjective symptoms. Each item of this questionnaire is rated from 0 (best) to 100 (worst) (25). We found that a total of two RCTs mentioned the relevant indicators in the King's health questionnaire and the forest plot results are shown as follows. In the part of General health perception, the scores of the experimental group were significantly decreased compared with the control group, and the difference was statistically significant (MD = -9.45, 95% CI = [-18.14, -0.77], P = 0.03). There was no significant difference between the experimental group and the control group in the effects of incontinence impact, role limitations and physical limitations (Incontinence impact: MD = -23.03, 95%CI = [-55.55, 9.48], P = 0.17; role limitations: MD = -10.34, 95% CI = [-33.72, 13.04], P = 0.39; physical limitations: MD = -15.21,95% CI = [-42.04, 11.61], P = 0.27). Besides, in the social limitations, personal relationship and emotions part, two

Dmochowski 2019 -1 Elmelund 2018 Franco 2011 -2 Terlikowski 2013 Ugurlucan 2012 Yildiz 2021 (Total (95% CI) Heterogeneity: Tau ² = 0.9 Test for overall effect: Z =		4.12 1.24 5.6 5.3 1.4 1.1	91 12 20 64 35 29		1.56 0.59 4.36	Total 89 11 22 29	Weight 21.8% 22.8% 7.4%	V, Random, 95% Cl -0.19 [-1.10, 0.72] -0.55 [-1.33, 0.23]	IV, Random, 95% Cl
Elmelund 2018 Franco 2011 -2 Terlikowski 2013 Ugurlucan 2012 Yildiz 2021 (Total (95% CI) Heterogeneity: Tau ² = 0.9 Test for overall effect: Z =	-0.1 2.83 6.7 0.9 0.68 93; Ch	1.24 5.6 5.3 1.4 1.1	12 20 64 35 29	0.45 -2.79 16.2 1.4	0.59 4.36 14.7	11 22	22.8%		
Franco 2011 -2 Terlikowski 2013 Ugurlucan 2012 Yildiz 2021 (Total (95% CI) Heterogeneity: Tau ² = 0.9 Test for overall effect: Z =	2.83 6.7 0.9 0.68 93; Ch	5.6 5.3 1.4 1.1	20 64 35 29	-2.79 16.2 1.4	4.36 14.7	22		-0.55 [-1.33, 0.23]	
Terlikowski 2013 Ugurlucan 2012 Yildiz 2021 (Total (95% CI) Heterogeneity: Tau ² = 0.9 Test for overall effect: Z =	6.7 0.9 0.68 93; Ch	5.3 1.4 1.1	64 35 29	16.2 1.4	14.7		7.4%		
Ugurlucan 2012 Yildiz 2021 (Total (95% CI) Heterogeneity: Tau ² = 0.9 Test for overall effect: Z =	0.9 0.68 93; Ch	1.4 1.1	35 29	1.4		29		-0.04 [-3.10, 3.02]	
Yildiz 2021 (Total (95% CI) Heterogeneity: Tau ² = 0.9 Test for overall effect: Z =	0.68 93; Ch	1.1	29		1.5			-9.50 [-15.01, -3.99]	
Total (95% CI) Heterogeneity: Tau² = 0.9 Test for overall effect: Z =	93; Ch			2.68		17	22.3%	-0.50 [-1.35, 0.35]	
Total (95% CI) Heterogeneity: Tau² = 0.9 Test for overall effect: Z =		i² = 21	054		1.83	29	22.9%	-2.00 [-2.78, -1.22]	*
Test for overall effect: Z =		i ² = 21	251				100.0%	-1.01 [-1.99, -0.03]	◆
	2.02			'= 5 (P =	= 0.000)7); l² =	77%		-10 -5 0 5 10
			,						Experimental Control
	Exper	iment	al	C	ontrol			Mean Difference	Mean Difference
Study or Subgroup M	lean	SD	Total	Mean	SD	Total	Weight	IV, Random, 95% Cl	IV, Random, 95% Cl
Franco 2011 (0.94	0.9	20	1.16	0.9	22	32.0%	-0.22 [-0.76, 0.32]	
Terlikowski 2013	6.7	4.7	64	14.6	12.4	29		-7.90 [-12.56, -3.24]	←
Ugurlucan 2012	-0.4	1	35	-0.2	1.1	17	30.7%	-0.20 [-0.82, 0.42]	
Yildiz 2021	0.89	0.9	29	1.86	0.58	29	34.5%	-0.97 [-1.36, -0.58]	-
Total (95% CI)			148			97	100.0%	-0.68 [-1.49, 0.12]	•
Heterogeneity: Tau ² = 0.4	45; Ch	i ² = 16	6.31, df	= 3 (P =	0.001	10); l ² =	82%		-10 -5 0 5 10
Test for overall effect: Z =	1.67	(P = 0.	.10)						-10 -5 0 5 10 Experimental Control
	Exper	iment	al	C	ontrol			Mean Difference	Mean Difference
Study or Subgroup M	lean	SD	Total	Mean	SD	Total	Weight	IV, Random, 95% Cl	IV, Random, 95% Cl
Amaro 2006	7	2.5	20	7.5	2.5	20	18.9%	-0.50 [-2.05, 1.05]	
Elmelund 2018	0.45	2.2	13	0.55	2.12	12	17.6%	-0.10 [-1.79, 1.59]	
Franco 2011 9	9.76	2.49	20	9	2.71	22	18.7%	0.76 [-0.81, 2.33]	
Terlikowski 2013 👘 4	47.2	12.4	64	48.6	18.6	29	2.0%	-1.40 [-8.82, 6.02]	
Ugurlucan 2012	5.8	1.9	35	7.4	2.9	17	19.2%	-1.60 [-3.12, -0.08]	
Yildiz 2021 8	6.51	1.95	29	8.79	2.27	29	23.6%	-2.28 [-3.37, -1.19]	
Total (95% CI)			181			129	100.0%	-0.84 [-1.92, 0.24]	•
Heterogeneity: Tau ² = 0.9				= 5 (P =	: 0.03)	; I ² = 59	9%		-10 -5 0 5 10
Test for overall effect: Z =	1.53	(P = 0.	.13)						Experimental Control
	-			-				Diff	
	Exper lean	riment SD		Co Mean	ontrol SD	Total	Weight	Mean Difference IV, Random, 95% Cl	Mean Difference IV, Random, 95% Cl
	0.44		91	-0.3	1	89	34.7%	-0.14 [-0.43, 0.15]	
	1.47		20	1.11		22	24.3%	0.36 [-1.01, 1.73]	
Terlikowski 2013	3.4	4.2	64	9.2	7.6	29	11.3%	-5.80 [-8.75, -2.85]	
	1.58		29	2.51	1.8	29	29.7%	-0.93 [-1.81, -0.05]	
Total (95% CI)			204			169	100.0%	-0.89 [-2.10, 0.31]	•
Heterogeneity: Tau ² = 1.0	07: Ch	i ² = 17		= 3 (P =	: 0.000			,	
Test for overall effect: Z =						.,			-10 -5 0 5 10
			-,						Experimental Control

RCTs identified that the improvement of the experimental group was significantly better than that of the control group (social limitations: MD = -13.91, 95% CI = [-26.16, -1.66], P = 0.03; personal relationship: MD = -11.69, 95% CI = [-20.41, -2.97], P = 0.009; emotions: MD = -29.03, 95% CI = [-52.16, -5.90], P = 0.01). In two studies comprising 97 participants (50 and 47 in the treatment and control group, respectively) reported sleep/energy and severity of urinary symptoms with an outcome respectively of MD = 0.68, 95% CI = [-17.42, 18.78], P = 0.94, and MD = -24.77, 95% CI = [-57.09, 7.55],

P = 0.13. Unfortunately, the difference in these two results was not statistically significant. The forest plots of all relevant King's health questionnaire results are shown in Figure 6.

Incontinence quality of life questionnaire

Incontinence quality of life (I-QOL) questionnaire score is another quality-of-life assessment questionnaire for patients with urinary incontinence. Each question in the questionnaire

Correia 2014 a Correia 2014 b		33.33 32.27 43.75 21.65	15 21.8% 15 37.8%	-6.67 [-25.27, 11.93] -17.09 [-31.21, -2.97]			
Ugurlucan 2012	39.5 22.5 35		17 40.4%	-3.80 [-17.47, 9.87]			
Total (95% CI) Heterogeneity: Tau² = Test for overall effect:			47 100.0%	-9.45 [-18.14, -0.77]	-50	-25 0 25 Experimental Control	50
Incontinence impact Study or Subgroup	Experimental Mean SD Tota	Control I Mean SD	Fotal Weight	Mean Difference IV, Random, 95% C		Mean Difference IV, Random, 95% Cl	
Correia 2014 a	4.44 11.73 1		15 35.7%	-2.16 [-11.33, 7.01]	1		
Correia 2014 b Ugurlucan 2012	54.4 35.5 3		15 32.3% 17 32.0%	-56.67 [-76.39, -36.95] -12.30 [-32.91, 8.31]			
Total (95% CI) Heterogeneity: Tau² = Test for overall effect	65 = 749.82; Chi² = 24.15 : Z = 1.39 (P = 0.17)		47 100.0% 01); I ² = 92%	-23.03 [-55.55, 9.48]	 -100	-50 0 50 Experimental Control	100
Role limitations	Experimental	Control	Total Moigh	Mean Difference t IV, Random, 95% (-	Mean Difference	
Study or Subgroup Correia 2014 a	-36.66 26.12 1	5 -34.44 42	Total Weigh 15 32.59	-2.22 [-27.25, 22.8	1]	IV, Random, 95% Cl	
Correia 2014 b Ugurlucan 2012	-36.66 26.12 1 49.1 33.6 3		15 33.29 17 34.49				
Total (95% CI)	6			· -10.34 [-33.72, 13.04	1		
Test for overall effect	= 275.25; Chi ² = 5.63, : Z = 0.87 (P = 0.39)	at = 2 (P = 0.06); F	= 64%		-100	-50 0 50 Experimental Control) 100
Physical limitations	Experimental	Control		Mean Difference		Mean Difference	
Study or Subgroup Correia 2014 a	Mean SD Total 1.1 4.3 15	1.1 4.3	otal Weight 15 37.7%	IV, Random, 95% Cl 0.00 [-3.08, 3.08]		IV, Random, 95% Cl	
Correia 2014 b Ugurlucan 2012	1.1 4.3 15 41.2 37.1 35	51.38 42.91 41.1 30.1	15 30.3% 17 31.9%	-50.28 [-72.10, -28.46] 0.10 [-18.76, 18.96]	-		
Total (95% CI)	65			-15.21 [-42.04, 11.61]			
Heterogeneity: Tau ² = Test for overall effect	= 493.85; Chi ² = 20.01 : Z = 1.11 (P = 0.27)	, df = 2 (P < 0.0001	l); l² = 90%		-100	-50 0 50 Experimental Control	100
Social limitations	Experimental	Control		Mean Difference		Mean Difference	
Study or Subgroup Correia 2014 a		al Mean SD 5 -16.7 32.71	Total Weight 15 28.1%			IV, Random, 95% Cl	
Correia 2014 b Ugurlucan 2012		5 -2.8 34.85 5 40.7 34.5	15 26.3% 17 45.5%				
Total (95% CI)		5		-13.91 [-26.16, -1.66]	г., I		
Heterogeneity: Tau ² : Test for overall effect	= 0.00; Chi ² = 0.85, df :: Z = 2.23 (P = 0.03)	= 2 (P = 0.65); I ² =	0%		-50	-25 0 25 Experimental Control	50
Personal relationship	Experimental	Control		Mean Difference		Mean Difference	
Study or Subgroup Correia 2014 a		al Mean SD 5 -4.44 11.73	Total Weight 15 46.0%			IV, Random, 95% Cl	
Correia 2014 b Ugurlucan 2012	-13.33 14.08 1 9.9 21.2 3	5 8.44 23.39 5 15.6 27.1	15 28.2% 17 25.8%				
Total (95% CI)	6			-11.69 [-20.41, -2.97]		-	
Heterogeneity: Tau ² = Test for overall effect	= 20.61; Chi² = 3.03, d : Z = 2.63 (P = 0.009)	f = 2 (P = 0.22); l ² =	= 34%		-50	-25 0 25 Experimental Control	50
Emotions	Experimental	Control		Mean Difference		Mean Difference	
Study or Subgroup Correia 2014 a	-45 33.77 1	5 -25 38.23	15 31.0%	IV, Random, 95% C -20.00 [-45.81, 5.81]	IV, Random, 95% Cl	
Correia 2014 b Ugurlucan 2012	-45 33.77 1 38 31.5 3		15 33.1% 17 35.9%	-52.40 [-76.04, -28.76 -15.30 [-36.08, 5.48			
Total (95% CI)	6:			-29.03 [-52.16, -5.90]			
Heterogeneity: Tau ² : Test for overall effect	= 275.57; Chi ² = 5.89, :: Z = 2.46 (P = 0.01)	ai = 2 (P = 0.05); P	·= bb%		-100	-50 0 50 Experimental Control	100
Sleep/energy	Experimental	Control		Mean Difference		Mean Difference	
Study or Subgroup Correia 2014 a	-14.44 28.08 1	5 -27.7 41.62		13.26 [-12.15, 38.67]		IV, Random, 95% Cl	
Correia 2014 b Ugurlucan 2012		5 0 0 5 35.9 25.6	15 17 65.0%	Not estimable -6.10 [-20.75, 8.55]			
Total (95% CI) Heterogeneity: Tau²: Test for overall effect	= 75.46; Chi ² = 1.67, d	5 f = 1 (P = 0.20); I ^z =	47 100.0% = 40%	0.68 [-17.42, 18.78]	-100	-50 0 50 Experimental Control	100
Severity	Experimental	Control		Mean Difference		Mean Difference	
Study or Subgroup Correia 2014 a Correia 2014 b Ugurlucan 2012	Mean SD Total 1.77 4.69 15 1.77 4.69 15 42.1 32.7 35	8.09 14.6 58.33 25.6	tal Weight 15 34.5% 15 33.3% - 17 32.2%	V, Random, 95% Cl -6.32 [-14.08, 1.44] 56.56 [-69.73, -43.39] -11.70 [-28.42, 5.02]		IV, Random, 95% Cl	
Total (95% CI)	65		47 100.0%	-24.77 [-57.09, 7.55]			
Heterogeneity: Tau ² Test for overall effec	= 772.01; Chi ² = 42.13 t: Z = 1.50 (P = 0.13)	', df=2 (P < 0.000	01); l² = 95%		-100	-50 0 50 Experimental Control	100





reflects whether urinary incontinence is causing trouble, and the quantitative score ranges from one (completely) to five (never) (26). This questionnaire was mentioned in three studies and the result identified that the changes in the experimental group were not statistically significant compared with the control group (MD = 10.70, 95% CI = [-10.30, 31.70], P = 0.32, Figure 7).

Pelvic floor muscle strength

Pelvic floor muscle (PFM) strength measurement is another index to evaluate the outcome of urinary incontinence and a total of two studies mentioned this indicator. The results showed that compared with the control group, the IVES treatment could not significantly improve the pelvic floor muscle strength of participants, and the difference was not statistically significant (MD = 0.4, 95% CI = [-0.04, 0.84], P = 0.08, Figure 8).

Subjective feeling

The subjective feeling after treatment is usually used as a parameter to evaluate the effect of IVES. A total of three studies involving 230 participants (104 and 126 in the IVES and control groups, respectively) reported this data. The heterogeneity was high in the two parts of data in which the participants' responses were cure or no change. However, after deleting one of the studies (20), the heterogeneity was significantly reduced, so only the remaining two RCTs were analyzed. The results identified that the "cure" response rate of the IVES group was higher than the control group and the results were statistically significant (OR = 3.90, 95% CI = [1.41, 10.79], P = 0.009), while the "better than before" or "no change" response rate of the experimental group was not statistically significant compared with the control group (Better than before: OR = 1.19, 95% CI = [0.40, 3.55], P= 0.75; No change: OR = 0.25, 95% CI = [0.04, 1.53], P = 0.13; Figure 9).

Subgroup analysis

According to different experimental designs, we divided the included RCTs into three categories: IVES vs. sham group, IVES united training vs. training, and IVES vs. other electrical stimulation. At the same time, we performed a subgroup analysis of pad test, frequency of urinary incontinence, and the number of daily micturition. Through data analysis, it was found that IVES and the IVES united training can significantly reduce the weight of urine pad compared with the sham group and simple training group (IVES VS sham group: MD = -6.58, 95% CI = [-11.34, -1.83], P = 0.007; IVES united training vs. training: MD = -19.78, 95% CI = [-28.40, -11.17], P< 0.00001) while there was no significant difference between the IVES and other electrical stimulation groups (IVES vs.

Cure	Experim	ental	Contr	ol		Odds Ratio		Odds Ratio	
Study or Subgroup	Events	Total	Events	Total	Weight	M-H, Random, 95% Cl		M-H, Random, 95% Cl	
Ugurlucan 2012	12	35	1	17	22.7%	8.35 [0.98, 70.77]			
Yildiz 2021	13	29	6	29	77.3%	3.11 [0.98, 9.92]			
Total (95% CI)		64		46	100.0%	3.90 [1.41, 10.79]		-	
Total events	25		7						
Heterogeneity: Tau ² =	0.00; Chi ²	= 0.65,	df = 1 (P	= 0.42)); I² = 0%		0.01		100
Test for overall effect:	Z = 2.62 (F	P = 0.00	9)				0.01	Control Experimental	100
Better than before	Experim		Contr			Odds Ratio		Odds Ratio	
Study or Subgroup	Events	Total	Events	Total		M-H, Random, 95% Cl		M-H, Random, 95% Cl	
Ugurlucan 2012	20	35	14	17	27.2%	0.29 [0.07, 1.18]			
Wang 2017	17	40	22	80	39.5%	1.95 [0.88, 4.32]		+	
Yildiz 2021	13	29	8	29	33.3%	2.13 [0.71, 6.37]		+	
Total (95% CI)		104		126	100.0%	1.19 [0.40, 3.55]		-	
Total events	50		44						
Heterogeneity: Tau² =				= 0.05)); I² = 67%	6	0.01	0.1 1 10	100
Test for overall effect:	Z = 0.32 (F	P = 0.75)				0.01	Control Experimental	100
No change	Experim	ental	Contr	ol		Odds Ratio		Odds Ratio	
Study or Subgroup	Events	Total	Events	Total	Weight	M-H, Random, 95% Cl		M-H, Random, 95% Cl	
Ugurlucan 2012	3	35	2	17	44.0%	0.70 [0.11, 4.66]			
Yildiz 2021	3	29	15	29	56.0%	0.11 [0.03, 0.44]	-		
Total (95% Cl)		64		46	100.0%	0.25 [0.04, 1.53]			
Total events	6		17						
Heterogeneity: Tau² = Test for overall effect:				= 0.12)); l² = 59%	6	0.01	0.1 1 10 Control Experimental	100
- /				= 0.12)); I² = 59%	5	0.01		10

sham group: MD = -0.04, 95% CI = [-4.34, 4.27], P = 0.99; Figure 10). In the subgroup analysis of the urinary incontinence frequency, compared with the sham group, IVES can reduce the frequency of urinary incontinence, while IVES is not significantly improved compared with other electrical stimulation group or bladder training group. In addition, there was also no statistically significant difference among the three subgroups in the subgroup analysis of the number of daily micturition. The detailed results are shown in the Supplementary Figures S1, S2.

Discussion

We conducted a systematic review and meta-analysis of nine RCT studies, including 657 participants, to evaluate the efficacy of IVES in the treatment of female urinary incontinence. The results identified that after treatment with IVES, the urine pad test and urinary incontinence frequency of patients were improved to a certain extent. In addition, the ratio of cure in the subjective feeling of patients in the experimental group was also better than that in the control group. Some indicators in the King's health questionnaire and I-QOL questionnaire had also improved, but there were still some other indicators' changes in the questionnaire that had no statistical significance. Besides, the improvement of PFM strength after the IVES treatment was also not satisfactory. The above results suggested that IVES may partially improve the symptoms of patients with urinary incontinence.

The clinical treatment methods for female urinary incontinence mainly include drug therapy, physical therapy, and surgical treatment (27-30). Among them, physical therapy has become the preferred treatment for many patients with urinary incontinence because of its relatively simple treatment, low medical cost, and almost no side effects and adverse reactions (31). Physical therapy mainly includes pelvic floor muscle training, bladder training, and nerve regulation (32-34). Electrical stimulation is a way of nerve regulation and it is to stimulate the afferent nerve, efferent nerve, or effector innervating the bladder by outputting appropriate current through the electrical stimulation device, so as to reduce the sensitivity of the bladder in patients and improve the state of overactive bladder (35, 36). At present, the common clinical electrical stimulation methods are to stimulate the common peroneal nerve, sacral nerve, and posterior tibial nerve in vitro, but there are few reports on the treatment of urinary

	Expe	eriment	al	C	ontrol			Mean Difference	Mean Difference
Study or Subgroup	Mean	SD	Total	Mean	SD	Total	Weight	IV, Random, 95% Cl	IV, Random, 95% Cl
1.1.1 vs sham group									
Amaro 2006	-5.87	5	20	-1.98	5	20	20.2%	-3.89 [-6.99, -0.79]	•
Correia 2014 b	0.41	0.78	15	7.62	15.27	15	14.2%	-7.21 [-14.95, 0.53]	
Terlikowski 2013	6.1	11.4	64	18.2	20.8	29	13.8%	-12.10 [-20.17, -4.03]	
Subtotal (95% CI)			99			64	48.2%	-6.58 [-11.34, -1.83]	•
Heterogeneity: Tau ² =	8.65; Ch	i ² = 3.7	5, df = 2	P = 0.1	5); l ² =	47%			
Test for overall effect:	Z = 2.71	(P = 0.0	107)						
1.1.2 vs other electric	: stimula	tion							
Correia 2014 a	0.41	0.78	15	3.31	12.1	15	16.4%	-2.90 [-9.04, 3.24]	
Dmochowski 2019	-9.89	19.99	91	-13.07	21.53	89	16.4%	3.18 [-2.89, 9.25]	+
Ugurlucan 2012	-14.2	15.3	35	-10.6	37	17	5.4%	-3.60 [-21.90, 14.70]	
Subtotal (95% CI)			141			121	38.2%	-0.04 [-4.34, 4.27]	•
Heterogeneity: Tau ² =	0.50; Ch	i ² = 2.0	6, df = 2	? (P = 0.3	36); I ² =	3%			
Test for overall effect:	Z = 0.02	(P = 0.9	9)						
1.1.3 vs training									
Elmelund 2018	-48.61	96.44	12	-19.55	49.48	11	0.6%	-29.06 [-90.97, 32.85]	
Yildiz 2021	7.05	11.97	29	26.65	20.69	29	13.0%	-19.60 [-28.30, -10.90]	
Subtotal (95% CI)			41			40	13.6%	-19.78 [-28.40, -11.17]	◆
Heterogeneity: Tau ² =	0.00; Ch	i ² = 0.0	9, df = 1	(P = 0.7)	77); 2 =	0%			
Test for overall effect:	Z = 4.50	(P < 0.0	0001)						
Total (95% CI)			281			225	100.0%	-6.34 [-11.24, -1.45]	•
Heterogeneity: Tau ² =	28.27; C	hi² = 22	.57, df	= 7 (P =	0.002);	l² = 699	%		+ + + + + + + + + + + + + + + + + + +
Test for overall effect: .	Z = 2.54	(P = 0.0	11)						Experimental Control
Test for subaroup diffe	erences:	Chi ² =	16.85. 0	if = 2 (P	= 0.000	2), ² =	88.1%		Experimental Control
URE 10									inverse variance; CI, confidence interval; df,

incontinence by transvaginal electrical stimulation of the pudendal nerve.

Urgent urinary incontinence (UUI) and stress urinary incontinence (SUI) are two common types of UI. UUI refers to the behavior of bladder urinating without conscious control, which is usually secondary to cystitis, neurogenic bladder, and severe bladder outlet obstruction. SUI refers to the involuntary outflow of urine when the intra-abdominal pressure increases suddenly (cough, sneeze, laugh, exercise, etc.). SUI is common in women with multiple deliveries or postmenopausal women, which is caused by the weakening or loss of tension in the anterior vaginal wall and pelvic floor supporting tissue. Among the nine included studies, three studies mentioned the impact of IVES on UUI (Ugurlucan, Yildiz, Wang), and another three articles mentioned the impact of IVES on SUI (Correia, Terlikowski, Dmochowski). Ugurlucan's and Yildiz's research showed that IVES can significantly reduce the frequency of urinary incontinence and urine pad weight in UUI patients, and the subjective cure rate and satisfaction were also significantly improved. The research results of Correia, Terlikowski, and Dmochowski showed that in addition to improving the symptoms of urinary incontinence and subjective cure rate of patients, the improvement of IVES in patients with SUI was also reflected in PFM contraction intensity and pressure.

Our meta-analysis results found that IVES could improve a portion of symptoms of UI patients, which is consistent with the results of Correia et al. (16) and Franco et al. (17). Amaro et

al. (18) and Elmelund et al. (24) found through their research that the control group and the experimental group achieved the same treatment effect, so they questioned the effectiveness of IVES, which may be caused by too few follow-up people (Amaro: 40; Elmelund: 27). Dmochowski et al. (21) and Wang (20) believed that the effect of the control group was better than that of the IVES group, which may be due to the fact that the control group was not treated with sham therapy but with other electrical stimulation methods. In addition, the research of Yildiz, Terlikowski, and Ugurlucan believed that although IVES had brought a certain degree of improvement and relief to patients' quality-of-life and symptoms, more research and longer follow-up time were still needed to evaluate the effect of IVES.

As a matter of interest, the subgroup analysis results showed that IVES and IVES united training could significantly reduce the weight of urine pads compared with the sham group and the simple training group. While compared with other electrical stimulation methods, the improvement of IVES was not obvious, and the difference was not statistically significant. These results suggested that we can consider using IVES combined training to treat female urinary incontinence. In addition, we also performed a subgroup analysis on the frequency of urinary incontinence and daily micturition, but we did not get statistically significant results.

In the process of data analysis, we found that some studies only provide sample median and interquartile range (IQR). Therefore, we, at last, used the formula to convert them into mean data and standard deviation to facilitate our statistics and comparison (37, 38).

This is the first meta-analysis to study the efficacy of IVES in the treatment of female urinary incontinence. Although the intention is novel and the included studies are high-quality randomized controlled trials, there are still some limitations. First, there are too many indicators to evaluate urinary incontinence, and the indicators used by different RCTs are not unified, so some indicators lack sufficient experimental data to support our analysis. Second, the application of IVES is not popular, so there are few relevant studies, which is not conducive to our subgroup analysis. Third, some indicators in the research are displayed through the median and interquartile spacing, and we must use the formula to convert the original data into mean and standard deviation to facilitate our final statistical analysis. This conversion process may bring some errors, which affect the final result. At last, our study did not report other indicators to evaluate urinary incontinence, such as urethral pressure, maximum bladder volume, and other questionnaires reflecting the quality of life of urinary incontinence, because only one randomized controlled trial reported these indicators, which is not conducive to our analysis of the data. In conclusion, we may need more unified indicators, more studies and results to help us evaluate the effect of IVES in the treatment of female urinary incontinence.

Conclusion

This meta-analysis of nine randomized controlled trials showed that IVES could partially improve some indicators reflecting UI, such as lightening the quality of urinary pad in urinary pad test, reducing the frequency of urinary incontinence, increasing the proportion of cure in subjective evaluation, etc. However, there were still some indicators that did not improve significantly. In general, IVES is gradually becoming a popular choice for the treatment of female UI because of its effectiveness and convenience, but more experimental data are still needed to support our conclusion.

Data availability statement

The original contributions presented in the study are included in the article/Supplementary material, further inquiries can be directed to the corresponding author/s.

References

1. Rogers RG, Pauls RN, Thakar R, Morin M, Kuhn A, Petri E, et al. An international Urogynecological association (IUGA)/international continence society (ICS) joint report on the terminology for the

Author contributions

HY, XZ, FS, GT, JW, and ZZ study concept and design. HY, XZ, FS, JW, and ZZ analysis and interpretation of data and preparation of the manuscript. JW and ZZ critical revision of the manuscript. All authors contributed to the article and approved the submitted version.

Funding

This work was supported by grants from the National Nature Science Foundation of China (Nos. 81870525 and 81572835) and Taishan Scholars Program of Shandong Province (No. tsqn201909199).

Conflict of interest

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Publisher's note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Supplementary material

The Supplementary Material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/ fneur.2022.933679/full#supplementary-material

SUPPLEMENTARY FIGURE S1

Forest plots showing the improvement of urinary incontinence frequency in each subgroup. SD, standard deviation; IV, inverse variance; CI, confidence interval; df, degrees of freedom.

SUPPLEMENTARY FIGURE S2

Forest plots showing the improvement of the number of daily micturition in each subgroup. SD, standard deviation; IV, inverse variance; CI, confidence interval; df, degrees of freedom.

assessment of sexual health of women with pelvic floor dysfunction. *Int Urogynecol J.* (2018) 29:647–66. doi: 10.1007/s00192-018-3 603-9 2. Baek JM, Song JY, Lee SJ, Park EK, Jeung IC, Kim CJ, et al. Caffeine Intake Is Associated with Urinary Incontinence in Korean Postmenopausal Women: Results from the Korean National Health and Nutrition Examination Survey. *PLoS One.* (2016) 11:e0149311. doi: 10.1371/journal.pone.0149311

3. Brown JS, Sawaya G, Thom DH, Grady D. Hysterectomy and urinary incontinence: a systematic review. *Lancet.* (2000) 356:535–9. doi: 10.1016/S0140-6736(00)02577-0

4. Choi JB, Yoon BI, Han KD, Hong SH, Ha US. Urinary incontinence is associated with the development of peptic ulcers in adult women: Data from the KNHANES IV. *Medicine*. (2017) 96:e8266. doi: 10.1097/MD.00000000008266

5. Minassian VA, Drutz HP, Al-Badr A. Urinary incontinence as a worldwide problem. *Int J Gynaecol Obstet.* (2003) 82:327– 38. doi: 10.1016/S0020-7292(03)00220-0

6. Sims J, Browning C, Lundgren-Lindquist B, Kendig H. Urinary incontinence in a community sample of older adults: prevalence and impact on quality of life. *Disabil Rehabil.* (2011) 33:1389–98. doi: 10.3109/09638288.2010.532284

7. Langemo D, Hanson D, Hunter S, Thompson P, Oh IE. Incontinence and incontinence-associated dermatitis. *Adv Skin Wound Care.* (2011) 24:126–40. doi: 10.1097/01.ASW.0000395037.28398.6c

8. Oh SJ, Ku JH, Choo MS, Yun JM, Kim DY, Park WH. Health-related quality of life and sexual function in women with stress urinary incontinence and overactive bladder. *Int J Urol.* (2008) 15:62–7. doi: 10.1111/j.1442-2042.2007.01905.x

9. Imamura M, Abrams P, Bain C, Buckley B, Cardozo L, Cody J, et al. Systematic review and economic modelling of the effectiveness and cost-effectiveness of nonsurgical treatments for women with stress urinary incontinence. *Health Technol Assess*. (2010) 14:1–188. doi: 10.3310/hta14400

10. Caldwell KP. The electrical control of sphincter incompetence. *Lancet.* (1963) 2:174–5. doi: 10.1016/S0140-6736(63)92807-1

11. Messelink EJ. The overactive bladder and the role of the pelvic floor muscles. *BJU Int.* (1999) 83:31–5. doi: 10.1046/j.1464-410X.83.s2.7.x

12. Brubaker L. Electrical stimulation in overactive bladder. Urology. (2000) 55:17-23. doi: 10.1016/S0090-4295(99)00488-4

13. Fall M, Lindström S. Electrical stimulation. A physiologic approach to the treatment of urinary incontinence. *Urol Clin North Am.* (1991) 18:393–407. doi: 10.1016/S0094-0143(21)01005-3

14. Schreiner L, Santos TG, dos Souza ABA de, Nygaard CC, Silva Filho IG da. Electrical stimulation for urinary incontinence in women: a systematic review. *Int Braz J Urol.* (2013) 39:454–64. doi: 10.1590/S1677-5538.IBJU.2013.04.02

15. Moher D, Liberati A, Tetzlaff J, Altman DG, PRISMA Group. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. *BMJ.* (2009) 339:b2535. doi: 10.1136/bmj.b2535

16. Correia GN, Pereira VS, Hirakawa HS, Driusso P. Effects of surface and intravaginal electrical stimulation in the treatment of women with stress urinary incontinence: randomized controlled trial. *Eur J Obstet Gynecol Reprod Biol.* (2014) 173:113–8. doi: 10.1016/j.ejogrb.2013.11.023

17. Franco M de M, Souza F de O, Vasconcelos ECLM de, Freitas MMS de, Ferreira CHJ. Avaliação da qualidade de vida e da perda urinária de mulheres com bexiga hiperativa tratadas com eletroestimulação transvaginal ou do nervo tibial. *Fisioter Pesqui*. (2011) 18:145–50. doi: 10.1590/S1809-29502011000200008

18. Amaro JL, Gameiro MO, Kawano PR, Padovani CR. Intravaginal electrical stimulation: a randomized, double-blind study on the treatment of mixed urinary incontinence. *Acta Obstet Gynecol Scand.* (2006) 85:619–22. doi:10.1080/00016340500495058

19. Gungor Ugurlucan F, Onal M, Aslan E, Ayyildiz Erkan H, Kizilkaya Beji N, Yalcin O. Comparison of the effects of electrical stimulation and posterior tibial nerve stimulation in the treatment of overactive bladder syndrome. *Gynecol Obstet Invest.* (2013) 75:46–52. doi: 10.1159/000343756

20. Wang S, Lv J, Feng X, Lv T. Efficacy of electrical pudendal nerve stimulation versus transvaginal electrical stimulation in treating female idiopathic urgency urinary incontinence. *J Urol.* (2017) 197:1496–501. doi: 10.1016/j.juro.2017.01.065

21. Dmochowski R, Lynch CM, Efros M, Cardozo L. External electrical stimulation compared with intravaginal electrical stimulation for the treatment of stress urinary incontinence in women: A randomized controlled noninferiority trial. *Neurourol Urodyn.* (2019) 38:1834–43. doi: 10.1002/nau.24066

22. Terlikowski R, Dobrzycka B, Kinalski M, Kuryliszyn-Moskal A, Terlikowski SJ. Transvaginal electrical stimulation with surface-EMG biofeedback in managing stress urinary incontinence in women of premenopausal age: a double-blind, placebo-controlled, randomized clinical trial. *Int Urogynecol J.* (2013) 24:1631–8. doi: 10.1007/s00192-013-2071-5

23. Yildiz N, Alkan H, Sarsan A. Efficacy of intravaginal electrical stimulation added to bladder training in women with idiopathic overactive bladder: A prospective randomized controlled trial. *Int braz j urol.* (2021) 47:1150–9. doi: 10.1590/s1677-5538.ibju.2021.0161

24. Elmelund M, Biering-Sørensen F, Due U, Klarskov N. The effect of pelvic floor muscle training and intravaginal electrical stimulation on urinary incontinence in women with incomplete spinal cord injury: an investigator-blinded parallel randomized clinical trial. *Int Urogynecol J.* (2018) 29:1597–606. doi: 10.1007/s00192-018-3 630-6

25. Hebbar S, Pandey H, Chawla A. Understanding King's Health Questionnaire (KHQ) in assessment of female urinary incontinence. *Int J Res Med Sci.* (2015) 3:531. doi: 10.5455/2320-6012.ijrms20150301

26. Nojomi M, Baharvand P, Moradi lakeh M, Patrick DL. Incontinence quality of life questionnaire (I-QOL): translation and validation study of the Iranian version. *Int Urogynecol J.* (2009) 20:575–9. doi: 10.1007/s00192-009-0 808-y

27. Zhang HL, Huang ZG, Qiu Y, Cheng X, Zou XQ, Liu TT. Tamsulosin for treatment of lower urinary tract symptoms in women: a systematic review and meta-analysis. *Int J Impot Res.* (2017) 29:148–56. doi: 10.1038/ijir.2017.12

28. Bai SW, Sohn WH, Chung DJ, Park JH, Kim SK. Comparison of the efficacy of Burch colposuspension, pubovaginal sling, and tension-free vaginal tape for stress urinary incontinence. *Int J Gynaecol Obstet.* (2005) 91:246–51. doi: 10.1016/j.ijgo.2005.08.023

29. El-Barky E, El-Shazly A, El-Wahab OA, Kehinde EO, Al-Hunayan A, Al-Awadi KA. Tension free vaginal tape versus Burch colposuspension for treatment of female stress urinary incontinence. *Int Urol Nephrol.* (2005) 37:277–81. doi: 10.1007/s11255-004-6101-6

30. Goldman HB, Amundsen CL, Mangel J, Grill J, Bennett M, Gustafson KJ, et al. Dorsal genital nerve stimulation for the treatment of overactive bladder symptoms. *Neurourol Urodyn*. (2008) 27:499–503. doi: 10.1002/nau.20544

31. Bø K. Physiotherapy management of urinary incontinence in females. J Physiother. (2020) 66:147-54. doi: 10.1016/j.jphys.2020.06.011

32. Wallace SL, Miller LD, Mishra K. Pelvic floor physical therapy in the treatment of pelvic floor dysfunction in women. *Curr Opin Obstet Gynecol.* (2019) 31:485–93. doi: 10.1097/GCO.000000000 000584

33. Ptak M, Ciećwiez S, Brodowska A, Starczewski A, Nawrocka-Rutkowska J, Diaz-Mohedo E, et al. The effect of pelvic floor muscles exercise on quality of life in women with stress urinary incontinence and its relationship with vaginal deliveries: a randomized trial. *Biomed Res Int.* (2019) 2019:5321864. doi: 10.1155/2019/53 21864

34. Hersh L, Salzman B. Clinical management of urinary incontinence in women. *Am Fam Physician.* (2013) 87:634–40.

35. Scaldazza CV, Morosetti C, Giampieretti R, Lorenzetti R, Baroni M. Percutaneous tibial nerve stimulation versus electrical stimulation with pelvic floor muscle training for overactive bladder syndrome in women: results of a randomized controlled study. *Int Braz J Urol.* (2017) 43:121-6. doi: 10.1590/s1677-5538.ibju.2015.0719

36. Iyer S, Laus K, Rugino A, Botros C, Lozo S, Botros SM, et al. Subjective and objective responses to PTNS and predictors for success: a retrospective cohort study of percutaneous tibial nerve stimulation for overactive bladder. *Int Urogynecol J.* (2019) 30:1253–9. doi: 10.1007/s00192-018-3822-0

37. Luo D, Wan X, Liu J, Tong T. Optimally estimating the sample mean from the sample size, median, mid-range, and/or mid-quartile range. *Stat Methods Med Res.* (2018) 27:1785-805. doi: 10.1177/09622802166 69183

38. Wan X, Wang W, Liu J, Tong T. Estimating the sample mean and standard deviation from the sample size, median, range and/or interquartile range. *BMC Med Res Methodol.* (2014) 14:135. doi: 10.1186/1471-2288-14-135